Therapeutic effects of imatinib and selective PDGF receptor inhibitor in a mouse model of systemic sclerosis
| Project/Area Number |
20790696
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | Showa University |
|---|
Principal Investigator |
IYODA Masayuki Showa University, 医学部・内科学講座腎臓内科学部門, 助教 (20384365)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2008: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | 強皮症 / imatinib / B細胞 / Imatinib / PDGF |
|---|
| Research Abstract |
We evaluated the therapeutic effects of imatinib on a mouse model of systemic sclerosis. Compared to controls, imatinib-treated tight skin (Tsk) mice had reduced dermal thickening(186.40±20.35 vs 101.96±16.64 μm, p <0.01). Furthermore, imatinib-treated mice had significantly reduced skin fibronectin, TGF-b and collagen type I mRNA expressions(collagen type I : -38% ; fibronectin:-46% ; TGF-β : -26%). In addition, imatinib treatment also significantly reduced the serum anti-Scl70 antibody levels compared to vehicle treatment(0.83±0.23 vs 0.38 ±0.05, p <0.05). Conclusion: Imatinib treatment showed therapeutic effects in Tsk mice. The results of this study suggest that imatinib may be a novel approach for treating systemic sclerosis.
|
Report
(3 results)
Research Products
(25 results)
